PEIJIA-B (09996) disclosed that Executive Director, Chief Executive Officer and Chairman of the Board Zhang Yizeng acquired HKD 15 million worth of company shares.

06:38 26/03/2026

Peijia Medical-B (09996) announced that the Board of Directors has been informed that Dr. Zhang Yibo, Executive Director, Chief Executive Officer, and Chairman of the Board of Directors of the Company, intends to continue purchasing shares of the Company on the open market through a company controlled by him, starting from March 26, 2026. The total expected cost of this increased shareholding is not expected to exceed HK$15 million.

PEIJIA-B (09996) announces that the Board of Directors has been informed that Dr. Zhang Yi, Executive Director, Chief Executive Officer, and Chairman of the Board of Directors of the Company, intends to continue purchasing the Company's shares in the open market through his controlled company, starting from March 26, 2026. The total expected cost of this shareholding increase is not expected to exceed HK$15 million.

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.

Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.

Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"